Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00863655
First received: March 16, 2009
Last updated: October 18, 2013
Last verified: October 2013
  Purpose

There are no treatments specifically approved after recurrence or progression on a NSAI. In light of the need for new treatment options for postmenopausal women after failure of prior non steroidal aromatase inhibitors (NSAI) therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + placebo in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer refractory to NSAI.


Condition Intervention Phase
Breast Cancer
Drug: Everolimus
Drug: Placebo
Drug: Exemestane
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. [ Time Frame: date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first ,reported between day of first patient randomized, 27 July 2009, until cut-off date 11 February 2011. ] [ Designated as safety issue: No ]
    Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.0). For patients with no target lesion, in the absence of new lesions, the overall lesion response at each assessment was one of following: Complete Response CR), Stable Disease SD), Unknown, or Progressive Disease (PD) based on non-target lesion responses. The following is considered progression among patients with lytic or mixed (lytic+sclerotic) bone lesions: appearance of ≥1 new lytic lesions in bone; the appearance of ≥ new lesions outside of bone and unequivocal progression of existing bone lesions.


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Every 3 months after End of Treatment + 28 days (every 6 weeks before) ] [ Designated as safety issue: No ]
    Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.

  • Overall Response Rate (ORR) [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
    ORR is defined as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST.

  • Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs) [ Time Frame: Continuous and every 6 weeks ] [ Designated as safety issue: Yes ]
    In addition to AEs/SAEs, shift from baseline in vital signs and laboratory results (hematology, blood chemistry) will be reported.

  • Qol Scores ECOG Performance Status [ Time Frame: Every 6 weeks ] [ Designated as safety issue: Yes ]
    Change in QoL scores over time and time to deterioration of ECOG performance status.

  • Clinical Benefit Rate (CBR) [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
    CBR is defined as the proportion of patients whose best overall response is either complete response (CR), a partial response (PR) or stable disease (SD) lasting for at least 24 weeks, according to RECIST.


Enrollment: 724
Study Start Date: June 2009
Estimated Study Completion Date: June 2014
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus + Exemestane
Everolimus 10 mg daily in combination with exemestane 25 mg daily
Drug: Everolimus
Everolimus was administered by continuous oral dosing of two 5-mg tablets.
Other Name: RAD001
Drug: Exemestane
Commercially available exemestane was supplied to sites as s25-mg tablets according to local regulations.
Active Comparator: Placebo + Exemestane
Placebo of everolimus in combination with exemestane 25 mg daily
Drug: Placebo
Placebo was formulated to be indistinguishable from the everolimus tablets.
Drug: Exemestane
Commercially available exemestane was supplied to sites as s25-mg tablets according to local regulations.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  • Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer
  • Postmenopausal women.
  • Disease refractory to non steroidal aromatase inhibitors (NSAI),
  • Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to randomization.
  • Patients must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease
  • Adequate bone marrow and coagulation function
  • Adequate liver and renal function
  • ECOG Performance Status = 2 or less

Exclusion Criteria:

  • HER2-overexpressing patients
  • Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites etc.).
  • Patients who received more than one chemotherapy line for Advanced Breast Cancer.
  • Previous treatment with exemestane or mTOR inhibitors.
  • Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).
  • Radiotherapy within four weeks prior to randomization
  • Currently receiving hormone replacement therapy,
  • Patients receiving immunosuppressive agents or chronic corticosteroids use
  • Patients being treated with strong inhibitors or inducers of CYP3A within 5 days prior to randomization

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00863655

  Hide Study Locations
Locations
United States, Arizona
Novartis Investigative Site
Chandler, Arizona, United States, 85224
United States, Arkansas
Novartis Investigative Site
Fayetteville, Arkansas, United States, 72703
United States, California
Novartis Investigative Site
Anaheim, California, United States, 92807
Novartis Investigative Site
Bakersfield, California, United States, 93309
Novartis Investigative Site
Beverly Hills, California, United States, 90211
Novartis Investigative Site
Fresno, California, United States, 93720
Novartis Investigative Site
Grass Valley, California, United States, 95945
Novartis Investigative Site
La Jolla, California, United States, 92121
Novartis Investigative Site
Los Angeles, California, United States, 90053
Novartis Investigative Site
Los Angeles, California, United States, 90025
Novartis Investigative Site
San Diego, California, United States, 92123
Novartis Investigative Site
San Francisco, California, United States, 94143
Novartis Investigative Site
Santa Monica, California, United States, 90404
Novartis Investigative Site
Santa Rosa, California, United States, 94503
United States, Florida
Novartis Investigative Site
Boca Raton, Florida, United States, 33248
Novartis Investigative Site
Davie, Florida, United States, 33328
Novartis Investigative Site
Fort Myers, Florida, United States, 33901
Novartis Investigative Site
Hollywood, Florida, United States, 33021
Novartis Investigative Site
Orlando, Florida, United States, 32806
Novartis Investigative Site
West Palm Beach, Florida, United States, 33401
Novartis Investigative Site
Zephyrhills, Florida, United States, 33542
United States, Georgia
Novartis Investigative Site
Columbus, Georgia, United States, 31904
Novartis Investigative Site
Decatur, Georgia, United States, 30033
United States, Illinois
Novartis Investigative Site
Chicago, Illinois, United States, 60612
Novartis Investigative Site
Park Ridge, Illinois, United States, 60068-0736
United States, Indiana
Novartis Investigative Site
Indianapolis, Indiana, United States, 46260
Novartis Investigative Site
Lafayette, Indiana, United States, 47905
United States, Kansas
Novartis Investigative Site
Wichita, Kansas, United States, 67214-3728
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40202
United States, Louisiana
Novartis Investigative Site
Baton Rouge, Louisiana, United States, 70808
Novartis Investigative Site
Metairie, Louisiana, United States, 70006
United States, Maryland
Novartis Investigative Site
Annapolis, Maryland, United States, 21401
Novartis Investigative Site
Baltimore, Maryland, United States, 21237
Novartis Investigative Site
Baltimore, Maryland, United States, 21237-3998
Novartis Investigative Site
Baltimore, Maryland, United States, 21202
Novartis Investigative Site
Frederick, Maryland, United States, 21701
Novartis Investigative Site
Silver Spring, Maryland, United States, 20910
United States, Massachusetts
Novartis Investigative Site
Burlington, Massachusetts, United States, 01805
United States, Minnesota
Novartis Investigative Site
Edina, Minnesota, United States, 55435
United States, Missouri
Novartis Investigative Site
St. Louis, Missouri, United States, 63141
United States, Nebraska
Novartis Investigative Site
Lincoln, Nebraska, United States, 68510
United States, New Jersey
Novartis Investigative Site
Cherry Hill, New Jersey, United States, 08003
Novartis Investigative Site
Elizabeth, New Jersey, United States, 07207
United States, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87131
United States, New York
Novartis Investigative Site
Lake Success, New York, United States, 11042
Novartis Investigative Site
New York, New York, United States, 10003
Novartis Investigative Site
New York, New York, United States, 10021
Novartis Investigative Site
Nyack, New York, United States, 10960
United States, North Carolina
Novartis Investigative Site
Washington, North Carolina, United States, 27889
United States, Oklahoma
Novartis Investigative Site
Lawton, Oklahoma, United States, 73505
Novartis Investigative Site
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
Novartis Investigative Site
Hershey, Pennsylvania, United States, 17033-0850
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29425
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis Investigative Site
Dallas, Texas, United States, 75390-8852
Novartis Investigative Site
Fort Worth, Texas, United States, 76104
Novartis Investigative Site
Houston, Texas, United States, 77030-4009
Novartis Investigative Site
Richardson, Texas, United States, 75080
United States, Utah
Novartis Investigative Site
Ogden, Utah, United States, 84403-3105
Novartis Investigative Site
Provo, Utah, United States, 84604
Novartis Investigative Site
Salt Lake City, Utah, United States, 84103
Novartis Investigative Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Novartis Investigative Site
Reston, Virginia, United States, 20190
United States, Wisconsin
Novartis Investigative Site
Madison, Wisconsin, United States, 53792
Australia, Queensland
Novartis Investigative Site
Nambour, Queensland, Australia, 4560
Novartis Investigative Site
Redcliffe, Queensland, Australia, 4020
Australia, South Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Novartis Investigative Site
Parkville, Victoria, Australia, 3050
Australia, Western Australia
Novartis Investigative Site
Subiaco, Western Australia, Australia, 6008
Austria
Novartis Investigative Site
Innsbruck, Austria, A-6020
Novartis Investigative Site
Linz, Austria, A-4010
Novartis Investigative Site
Salzburg, Austria, 5020
Novartis Investigative Site
Wels, Austria, A-4600
Novartis Investigative Site
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Jette, Belgium, 1090
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
St. Niklaas, Belgium, 9100
Novartis Investigative Site
Wilrijk, Belgium, 2610
Brazil
Novartis Investigative Site
Salvador, BA, Brazil, 41825-010
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30150-281
Novartis Investigative Site
Uberlândia, MG, Brazil, 38408-150
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 20230-130
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 22640-000
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90035-903
Novartis Investigative Site
São Paulo, SP, Brazil, 01246-000
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 4N2
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Novartis Investigative Site
Cambridge, Ontario, Canada, N1R 3G2
Novartis Investigative Site
London, Ontario, Canada, N6A 4L6
Novartis Investigative Site
Newmarket, Ontario, Canada, L3Y 5G8
Novartis Investigative Site
St. Catharines, Ontario, Canada, L2R 7C6
Novartis Investigative Site
Toronto, Ontario, Canada, M4C 3E7
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Novartis Investigative Site
Weston, Ontario, Canada, M9N 1N8
Canada, Quebec
Novartis Investigative Site
Greenfield Park, Quebec, Canada, J4V 2H1
Novartis Investigative Site
Montreal, Quebec, Canada, H2W1S6
Novartis Investigative Site
Montreal, Quebec, Canada, H4J 1C5
Novartis Investigative Site
Montreal, Quebec, Canada, H2W 1T8
Novartis Investigative Site
Sherbrooke, Quebec, Canada, J1H 5N4
Canada
Novartis Investigative Site
Quebec, Canada, G1S 4L8
Czech Republic
Novartis Investigative Site
Olomouc, CZE, Czech Republic, 775 20
Novartis Investigative Site
Brno, Czech Republic, 656 53
Novartis Investigative Site
Praha, Czech Republic, 14044
Egypt
Novartis Investigative Site
Alexandria, Egypt
Novartis Investigative Site
Cairo, Egypt
Novartis Investigative Site
Menoufiya, Egypt
France
Novartis Investigative Site
La Roche sur Yon Cedex, France, 85925
Novartis Investigative Site
Le Mans, France, 72000
Novartis Investigative Site
Lyon Cedex, France, 69373
Novartis Investigative Site
Marseille, France, 13008
Novartis Investigative Site
Paris, France, 75010
Novartis Investigative Site
Rouen, France, 76000
Novartis Investigative Site
Rouen Cedex 1, France, 76038
Novartis Investigative Site
Saint-Herblain Cédex, France, 44805
Novartis Investigative Site
Saint-Nazaire, France, 44600
Germany
Novartis Investigative Site
Augsburg, Germany, 86150
Novartis Investigative Site
Berlin, Germany, 10098
Novartis Investigative Site
Duesseldorf, Germany, 40225
Novartis Investigative Site
Frankfurt, Germany, 60389
Novartis Investigative Site
Mannheim, Germany, 68161
Novartis Investigative Site
Muenchen, Germany, 81377
Novartis Investigative Site
Muenchen, Germany, 80637
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
Trier, Germany, 54290
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Hong Kong SAR, Hong Kong
Hungary
Novartis Investigative Site
Budapest, Hungary, H-1122
Novartis Investigative Site
Szeged, Hungary, H-6720
Novartis Investigative Site
Szolnok, Hungary, H-5000
Italy
Novartis Investigative Site
Brindisi, BR, Italy, 72100
Novartis Investigative Site
Catania, CT, Italy, 95100
Novartis Investigative Site
Bagno a Ripoli, FI, Italy, 50011
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Macerata, MC, Italy, 62100
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Torino, TO, Italy, 10126
Novartis Investigative Site
Terni, TR, Italy, 05100
Novartis Investigative Site
Saronno, Va, Italy, 21047
Novartis Investigative Site
Varese, VA, Italy, 21100
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 464-8681
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277-8577
Novartis Investigative Site
Matsuyama, Ehime, Japan, 791-0280
Novartis Investigative Site
Kitakyushu, Fukuoka, Japan, 802-0077
Novartis Investigative Site
Maebashi, Gunma, Japan, 371-8511
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 060-8648
Novartis Investigative Site
Isehara, Kanagawa, Japan, 259-1193
Novartis Investigative Site
Suita, Osaka, Japan, 565-0871
Novartis Investigative Site
Hidaka, Saitama, Japan, 350-1241
Novartis Investigative Site
Kitaadachi-gun, Saitama, Japan, 338-8553
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8677
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 104-0045
Novartis Investigative Site
Cyuo-ku, Tokyo, Japan, 104-8560
Novartis Investigative Site
Koto, Tokyo, Japan, 135-8550
Novartis Investigative Site
Fukuoka, Japan, 811-1395
Novartis Investigative Site
Kagoshima, Japan, 892-0833
Novartis Investigative Site
Kumamoto, Japan, 860-8556
Novartis Investigative Site
Kyoto, Japan, 606-8507
Novartis Investigative Site
Osaka, Japan, 537-8511
Novartis Investigative Site
Osaka, Japan, 540-0006
Korea, Republic of
Novartis Investigative Site
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 120-752
Novartis Investigative Site
Seoul, Korea, Republic of, 139-706
Netherlands
Novartis Investigative Site
Alkmaar, Netherlands, 1815 JD
Novartis Investigative Site
Amsterdam, Netherlands, 1090 HM
Novartis Investigative Site
Den Haag, Netherlands, 2545 CH
Novartis Investigative Site
Dordrecht, Netherlands, 3318AT
Novartis Investigative Site
Eindhoven, Netherlands, 5631 BM
Novartis Investigative Site
Sittard-Geleen, Netherlands, 6162 BG
New Zealand
Novartis Investigative Site
Christchurch, New Zealand, 8001
Norway
Novartis Investigative Site
Lørenskog, Norway, NO-1478
Poland
Novartis Investigative Site
Krakow, Poland, 31-108
Novartis Investigative Site
Rzeszow, Poland, 35922
Novartis Investigative Site
Warszawa, Poland, 04-125
Spain
Novartis Investigative Site
Santiago de Compostela, A Coruña, Spain, 15706
Novartis Investigative Site
Terrassa, Barcelona, Spain, 08221
Novartis Investigative Site
Torrevieja (Alicante), Comunidad Valenciana, Spain, 03186
Novartis Investigative Site
Mallorca, Islas Baleares, Spain, 07198
Novartis Investigative Site
Palma De Mallorca, Mallorca, Spain, 07014
Novartis Investigative Site
Barcelona, Spain, 08035
Novartis Investigative Site
La Coruña, Spain, 15006
Novartis Investigative Site
Lleida, Spain, 25198
Novartis Investigative Site
Madrid, Spain, 28033
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Malaga, Spain, 29010
Novartis Investigative Site
Sevilla, Spain, 41017
Sweden
Novartis Investigative Site
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
Stockholm, Sweden, SE-118 83
Novartis Investigative Site
Uppsala, Sweden, SE-751 85
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Bangkok, Thailand, 10400
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Novartis Investigative Site
Songkla, Thailand, 90110
Turkey
Novartis Investigative Site
Altunizade, Turkey, 34662
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Izmir, Turkey, 35040
United Kingdom
Novartis Investigative Site
Broomfield, Chelmsford, United Kingdom, CM1 7ET
Novartis Investigative Site
Truro, Cornwall, United Kingdom, TR1 3LJ
Novartis Investigative Site
Cardiff, United Kingdom, CF14 2TL
Novartis Investigative Site
Nottingham, United Kingdom, NG5 1BP
Novartis Investigative Site
Sheffield, United Kingdom, S10 2SJ
Novartis Investigative Site
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticlas Novartis Pharmaceuticals
  More Information

Additional Information:
No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00863655     History of Changes
Other Study ID Numbers: CRAD001Y2301, 2008-008698-69
Study First Received: March 16, 2009
Results First Received: July 31, 2012
Last Updated: October 18, 2013
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria: Agency for Health and Food Safety
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Brazil: National Health Surveillance Agency
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Egypt: Ministry of Health, Drug Policy and Planning Center
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
Italy: National Institute of Health
Japan: Pharmaceuticals and Medical Devices Agency
Netherlands: Medicines Evaluation Board (MEB)
New Zealand: Food Safety Authority
Norway: Norwegian Medicines Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
South Korea: Korea Food and Drug Administration (KFDA)
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Thailand: Food and Drug Administration
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
Breast Cancer
Estrogen Receptor positive
ER+
exemestane
mTOR
everolimus
refractory
NSAI

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Everolimus
Sirolimus
Anastrozole
Exemestane
Estrogens
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014